Research programme: vaccines - Mariposa Health

Drug Profile

Research programme: vaccines - Mariposa Health

Alternative Names: Golden staph vaccine - Hunter Immunology; H 003; H 003 plus adjuvant; MH 003

Latest Information Update: 07 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hunter Immunology
  • Developer Mariposa Health Limited
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Staphylococcal infections
  • Discontinued Candidiasis; Pseudomonal infections

Most Recent Events

  • 07 Jan 2016 Discontinued - Preclinical for Candidiasis in Australia (PO)
  • 07 Jan 2016 Discontinued - Preclinical for Pseudomonal infections in Australia (PO)
  • 25 Jun 2015 Preclinical trials in Staphylococcal infections in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top